Narrow Your Results

To further understand the systemic and ocular risk factors for rapid glaucoma progression, investigators examined a cohort of rapid and nonrapid disease progressors.

Aldeyra Therapeutics has announced positive results from their phase 2a clinical trial investigating the optimal dose of the dry eye treatment candidate, ADX-102.

Using data from a large randomized trial, investigators analyzed intra- and post-operative factors that are vital in shaping trichiasis surgery outcomes.

This prospective noncomparative case series study evaluated the results of piggyback collagen collamer lens implantation for correction of pseudophakic refractive error after cataract surgery.

Allergan has sold the patents for Restasis to a Native American tribe in an effort to protect their top-selling dry eye drug from generic competition.

Novartis will undergo a significant change in leadership with the announcement that Joseph Jimenez will step down after an 8-year stint as CEO.

This retrospective study assessed long-term outcomes of tocilizumab therapy for treatment of vision-impacting uveitis-associated macular edema refractory to traditional immunosuppressive and biological agents.

This prospective study compared the accuracy of automated toric IOL alignment to conventional manual ink-marking.

This single-center, retrospective study evaluated the incidence and risk factors for corneal breakthrough haze following photorefractive keratectomy (PRK) with mitomycin c (MMC).

Promising results from a phase 2 study indicate that Apellis Pharmaceuticals’ conjugated peptide candidate (APL-2) is effective at slowing progression of geographic atrophy associated with AMD.

This retrospective, interventional case series is the largest study to date assessing the effectiveness of rituximab for autoimmune retinopathy (AIR).

Vital Rx, Inc. d/b/a Atlantic Pharmacy and Compounding is voluntarily recalling all lots of its compounded injectable prescription medications due to lack of sterility assurance.

Topline results from a phase 2 study demonstrated that Allegro Ophthalmic’s first-in-class anti-integrin candidate, Luminate, can help restore vision in diabetic macular edema (DME) patients being treated with anti-VEGF therapy.

In this secondary analysis of the Telemedicine Approaches to Evaluating Acute-phase ROP (e-ROP) study, investigators examined the intereye agreement of ROP features and severity using trained nonphysician graders.

This retrospective study analyzed outcomes for ab interno bleb revisions using the Grover-Fellman biplanar sclerostomy spatula.

Researchers at the London Retinoblastoma Service found that patients with salvaged group D eyes have a high likelihood of poor visual acuity and strabismus after treatment.

Regeneron Pharmaceuticals reported a significantly better-than-expected quarterly profit, fueled by strong demand for its flagship anti-VEGF drug, aflibercept (Eyelea).

Cantrell Drug Company has issued a voluntary nationwide recall of unexpired sterile drug products due to concerns over sterility assurance.

A retrospective analysis of more than 600,000 cataract surgeries found that use of intracameral (IC) moxifloxacin prophylaxis significantly lowered rates of postoperative endophthalmitis.

The key to zebrafish regenerating retinal tissue may lie within their microglia cells, according to scientists from Johns Hopkins University School of Medicine.

An investigational gene therapy for inherited retinal dystrophies has received priority review designation from the FDA following promising results from several clinical trials.

In this retrospective study, investigators examined the presence of a triangle-shaped tissue resembling a wedge in patients with biopsy-proven lacrimal gland disease.

EvokeDx, a device capable of objectively assessing central vision function and diagnosing glaucoma, has received the CE mark, according to a press release from manufacturer Konan Medical.

Surgeons from the United Kingdom reported the removal of 27 contact lenses from a 67-year-old patient’s eye, found at the beginning of routine cataract surgery.

The FDA has removed approval for Par Pharmaceutical’s epinephrine formulation, Adrenalin^®, for ophthalmic use.